AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01011855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GEHC IWS 4400 & Giraffe Warmer beds
Description: Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
Study NCT03946787 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) Therapy
Description: The reprocessing and desensitization of each traumatic memory occurs in eight phases. In the first two phases, the therapist identifies targets and develops a treatment plan, enhances and develops personal resources, before working on traumatic memories. In stages 3 to 6, reprocessing and desensitization of memory is done. The patient focuses on the image of the event, negative beliefs and associated bodily sensations, while moving the eyes from side to side, following the therapist's fingers or other dual attention stimuli (eg, manual touch, auditory stimulation). Phases 7 and 8 are closing and reassessing, where the therapist determines if the memory has been processed properly.
Study NCT03946787 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service.
Study NCT03946787 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: TAU will consist of the psychopharmacological approach appropriate to each patient according to the evaluation of a psychiatrist of childhood and adolescence's outpatient service.
Study NCT01261832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiplatelet therapy
Description: Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with aspirin,clopidogrel and cilostazol.
Study NCT00474058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum Rotigotine dose allowed is 16mg/24h
Study NCT00474058 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo transdermal patches
Study NCT02638922 — intervention group
Intervention type: DRUG
Intervention: Estradiol
Description: Estradiol containing compounds administered orally in a non-randomized manner.
Study NCT00214500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: migalastat HCl
Study NCT03085277 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine Colostrum
Description: Bovine colostrum (BC) is the first milk from cows after birth and we suggest that BC may be used to supplement MM, instead of infant formula or DM. BC is a rich source of protein (up to 150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and various growth factors, such as, IGF-I and -II, EGFs, and TGF-β. BC has repeatedly been shown to have beneficial effects in a well-established piglet model of preterm infants, using various feeding regimens, including a gradual regimen that would mimic enteral feeding for preterm infants without access to MM during the first week.
Study NCT03085277 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Preterm Formula
Description: Preterm formula is a type of infant formula designed for preterm infants. It is used when mother's own milk is not available or not in sufficient amount as the enteral feeding for preterm infants in hospitals that do not have donor human milk.
Study NCT00586326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MammoSite Radiation Therapy System
Description: The MammoSite is a balloon catheter that is designed to position a radioactive source inside the lumpectomy cavity. The MammoSite applicator is inserted into the cavity created by the tumor removal surgery. The MammoSite applicator is then inflated and expands to fill the cavity.
Study NCT04584697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-AMG
Description: COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb).
Study NCT04584697 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent solution
Study NCT03504579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rt-fMRI neurofeedback
Description: use of real time fMRI neurofeedback to achieve targeted brain changes
Study NCT03504579 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: rt-fMRI neurofeedback
Description: use of real time fMRI neurofeedback to achieve targeted brain changes
Study NCT01451268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: 10mg upto 40mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every week; duration: one year
Study NCT01451268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Start of Arm B after completion of Arm A; initial dose-level: one level below MTD of Arm A; 10mg upto 60mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every other week; duration: one year
Study NCT03221075 — intervention group
Intervention type: OTHER
Intervention: Registry
Description: There is no intervention.
Study NCT02182648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etomidate
Description: 1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. infusion of etomidate at 2 minutes before anesthesia induction
Study NCT02182648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: 1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. infusion of propofol at 2 minutes before anesthesia induction
Study NCT02182648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: 1. intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.~2. inhale sevoflurane for anesthesia induction and maintenance
Study NCT03582644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
Study NCT00112697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00112697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00112697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00112697 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT01997710 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: all-ceramic inlay-retained RBFDP
Description: Rehabilitation of tooth loss with an all-ceramic inlay-retained RBFDP
Study NCT01997710 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: all-ceramic RBFDP
Description: Rehabilitation of tooth loss with an all-ceramic RBFDP
Study NCT01151098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear
Study NCT02359162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine :1250mg/m2 (ivdrip) on days 1
Study NCT02359162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin :85 mg/m2 (ivdrip) on day 1
Study NCT02359162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: pegaspargase : 2500 IU/m2 (intramuscular injection)
Study NCT02359162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: 50 mg/m 2 /day 24 h continuous infusion on days 1-4
Study NCT02359162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: 0.4 mg/m 2 /day 24 h continuous infusion on days 1-4
Study NCT02359162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 10 mg/m 2 /day 24 h continuous infusion on days 1-4
Study NCT02359162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: cyclophosphamide 750 mg/m2 /day over 15 min intravenously on day 5
Study NCT02359162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 60 mg/m 2 /day 60 mg/m 2 /day on days 1-5
Study NCT02359162 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.
Study NCT02359162 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.
Study NCT03931668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-672
Description: single dose of TPN-672 maleate tablet
Study NCT04384588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma from COVID-19 donors
Description: Patients that will participate in this clinical trial will be treated with Convalescent Plasma from COVID-19 donors regardless of the arm where they will be included
Study NCT05791370 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A 12-week parallel dietary intervention
Description: Subjects consumed 3 isocaloric meals prepared with the 3 oils for a duration of 12 weeks. The test meals were given for 5-day a week and contained 27-30% energy fat, with 2/3 (20% energy fat) replaced by experimental fat.
Study NCT01489371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01489371 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1
Description: Given IP
Study NCT01489371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study NCT01411930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine, aripiprazole
Description: 1. 1st clamp: single intramuscular 10.0 mg dose of olanzapine~2. 2nd clamp: single intramuscular 9.75 mg dose of aripiprazole
Study NCT01411930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular aripiprazole, olanzapine
Description: 1. 1st clamp: single intramuscular 9.75 mg dose of aripiprazole~2. 2nd clamp: single intramuscular 10.0 mg dose of olanzapine
Study NCT02317146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium sulfate is the drug used as prophylaxis to eclampsia in women with severe preeclampsia
Study NCT02317146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Magnesium sulfate is the drug used as prophylaxis to eclampsia in women with severe preeclampsia
Study NCT00959335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)
Study NCT00959335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
Study NCT04246255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine 10% Oral
Description: 50 ml of lidocaine solution maintained from xylocaine 10% oral that transferred to a bottle with a spray pump which pumps 0,1ml for each pump will be used for the experiment.~3 pumps of lidocaine will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted.
Study NCT04246255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- Serum Fizyolojik Izotonik 0,9% 10 ml ampul
Description: 50 ml of Serum physiologic in a bottle with a spray pump which pumps 0,1ml for each pump will be used for placebo.~3 pumps of placebo will be administrated to 3M TegadermTM +Pad Film Dressing with Non-Adherent Pad and put onto the skin for 10 minutes that IV cannula planned to be inserted.
Study NCT03706898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida®
Description: Elpida® capsules, 20mg
Study NCT00388141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIDCAP
Description: Systematic care, where the mother and the nurses organize the caring on behalf of the preterm infants' ressources and developmental capacity such as the infant avoid over stimulation and distress
Study NCT01526746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: 20mg capsule, once
Study NCT01526746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: 20mg, once
Study NCT01315743 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Team COOL
Description: 1) a classroom-based experiential curriculum that incorporated school, family and community-linked activities to promote physical activity, healthy eating and limited television viewing, 2) environmental modifications of food and beverage offerings and physical activity opportunities at school and 3) a teacher-guided, youth-directed health advisory council to promote and support physical activity, healthy eating and limited television viewing.
Study NCT03975647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300mg given twice per day by mouth (orally)
Study NCT03975647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given twice per day orally
Study NCT03975647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T-DM1
Description: 3.6 mg/kg given into the vein (IV; intravenously) every 21 days
Study NCT03975647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: 3.6 mg/kg given into the vein (IV; intravenously) every 21 days
Study NCT03451305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pillow
Description: A soft pillow was placed under the segment of the collapsed vertebrae, which resulted in a hyperextension position
Study NCT02953964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: perceptual-based memory encoding training
Description: Participants are trained in the use of perceptual-based memory encoding strategies, inclusive of visual imagery and the method of loci. Visual imagery involves the creation and encoding of mental images, while the method of loci refers to linking these images with specific places to facilitate memory (Simon et al., 2012). Participants are taught to visualise performing each step of a task in a familiar environment, such as in their home (Liu et al., 2009). After participants can correctly visualise the entire task, they then progress to actually performing the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
Study NCT02953964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral: semantic-based memory encoding training
Description: Participants are asked to encode the steps of a task by forming an association of the steps and sequence. Participants are trained in the use of the chunking association method and honeycomb concept and perform different tasks each week, implementing this encoding strategy (Lim et al., 2012). The chunking association method breaks down information into smaller parts and helps with the encoding and retrieval of information. The honeycomb concept allows the steps to form a story in relation to place, time, characters, problem and solution and the story is verbalised. Participants then complete the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
Study NCT02953964 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Cognitive stimulation group (control group)
Description: Participants receiving cognitive stimulation intervention. It consists of eight sessions that train participants' visual attention and memory, auditory attention and memory and their application in daily activities. Two sessions are also given which allow for participants to apply the training practically in their daily lives. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
Study NCT04043104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1: 1 x 10^11 vg/gland (single gland)
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^11 vg/gland
Study NCT04043104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1: 3 x 10^10 vg/gland (both glands)
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^10 vg/gland
Study NCT04043104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1: 3 x 10^11 vg/gland (single gland)
Description: Intra-parotid administration of AAV2hAQP1 of via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^11 vg/gland
Study NCT04043104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1: 1 x 10^11 vg/gland (both glands)
Description: intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^11 vg/gland
Study NCT04043104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1: 1 x 10^12 vg/gland (single gland)
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 1 x 10\^12 vg/gland
Study NCT04043104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1: 3 x 10^11 vg/gland (both glands)
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 3 x 10\^11 vg/gland
Study NCT04043104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1: 3 x 10^12 vg/gland (single gland)
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to a single parotid gland at a dose level of 3 x 10\^12 vg/gland
Study NCT04043104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2hAQP1: 1 x 10^12 vg/gland (both glands)
Description: Intra-parotid administration of AAV2hAQP1 via Stensen's duct to both parotid glands at a dose level of 1 x 10\^12 vg/gland
Study NCT00676962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External facilitation
Description: Study facilitator meets regularly with therapists to aid implementation of CBT
Study NCT02071654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus P-valve transcatheter implantation
Description: Percutaneous implantation of Venus-P valve to treat RVOT stenosis patients
Study NCT03598764 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Classic head extraction during Cesarean section
Description: by putting the fingers of the right inside the lower uterine segment to deliver the head
Study NCT03598764 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: External pop out technique
Description: The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not directly on the fetal head.
Study NCT00452530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 40 mg, administered once daily by subcutaneous injection, for 12 days
Study NCT00452530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: 2.5 mg, administered twice daily as tablets, for 12 days
Study NCT00452530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin-matching placebo
Description: Administered once daily by subcutaneous injection
Study NCT00452530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban-matching placebo
Description: Oral tablet administered twice daily